Anna Marie Mulligan

List of Publications by Year
in descending order

111	12,964	38660 50	26548 107
papers	citations	h-index	g-index

120	120	120	16021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	9.4	960
3	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
4	Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies. Journal of the National Cancer Institute, 2011, 103, 250-263.	3.0	596
5	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	13.9	532
6	Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 134-147.	1.1	513
7	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
8	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	9.4	493
9	Prediction of Breast Cancer Risk Based on Profiling With Common Genetic Variants. Journal of the National Cancer Institute, 2015, 107, .	3.0	428
10	Genome-wide association studies identify four ER negativeâ€"specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	9.4	374
11	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
12	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
13	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	9.4	265
14	Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nature Genetics, 2012, 44, 312-318.	9.4	256
15	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
16	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
17	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
18	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. American Journal of Human Genetics, 2013, 92, 489-503.	2.6	201

#	Article	IF	Citations
19	High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Modern Pathology, 2007, 20, 685-693.	2.9	194
20	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
21	PALB2,CHEK2andATMrare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
22	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
23	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
24	JAG1 expression is associated with a basal phenotype and recurrence in lymph node-negative breast cancer. Breast Cancer Research and Treatment, 2008, 111, 439-448.	1.1	138
25	Germline Mutation in BRCA1 or BRCA2 and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
26	Evidence of Geneâ€“Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
27	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
28	Papillary Lesions of the Breast. Advances in Anatomic Pathology, 2007, 14, 108-119.	2.4	122
29	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
30	Tumoral Lymphocytic Infiltration and Expression of the Chemokine CXCL10 in Breast Cancers from the Ontario Familial Breast Cancer Registry. Clinical Cancer Research, 2013, 19, 336-346.	3.2	113
31	19p13.1 Is a Triple-Negativeâ€“Specific Breast Cancer Susceptibility Locus. Cancer Research, 2012, 72, 1795-1803.	0.4	100
32	Metastatic Potential of Encapsulated (Intracystic) Papillary Carcinoma of the Breast: A Report of 2 Cases With Axillary Lymph Node Micrometastases. International Journal of Surgical Pathology, 2007, 15, 143-147.	0.4	99
33	Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Research and Treatment, 2007, 106, 39-47.	1.1	92
34	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
35	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
36	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88

#	Article	IF	Citations
37	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
38	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
39	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival. OncoImmunology, 2018, 7, e1509820.	2.1	80
40	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers. Breast Cancer Research, 2012, 14, R33.	2.2	78
41	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
42	Histologic Artifacts in Abdominal, Vaginal, Laparoscopic, and Robotic Hysterectomy Specimens. American Journal of Surgical Pathology, 2011, 35, 115-126.	2.1	74
43	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2011, 13, R110.	2.2	71
44	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortiumâ€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
45	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutationâ€positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. Cancer, 2012, 118, 681-688.	2.0	71
46	Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1301-E1310.	3.3	61
47	The Effect of Prolonged Fixation on the Immunohistochemical Evaluation of Estrogen Receptor, Progesterone Receptor, and HER2 Expression in Invasive Breast Cancer. American Journal of Surgical Pathology, 2011, 35, 545-552.	2.1	60
48	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	2.2	57
49	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
50	Cytokeratin 5 and Estrogen Receptor Immunohistochemistry as a Useful Adjunct in Identifying Atypical Papillary Lesions on Breast Needle Core Biopsy. American Journal of Surgical Pathology, 2009, 33, 1615-1623.	2.1	54
51	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
52	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
53	Papillary Lesions of the Breast. American Journal of Surgical Pathology, 2012, 36, 544-551.	2.1	50
54	MicroRNA Related Polymorphisms and Breast Cancer Risk. PLoS ONE, 2014, 9, e109973.	1.1	49

#	Article	IF	Citations
55	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
56	Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 645-657.	1.1	47
57	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	1.5	47
58	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
59	Genetic predisposition to ductal carcinoma in situ of the breast. Breast Cancer Research, 2016, 18, 22.	2.2	43
60	Clinicalâ€“pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Research and Treatment, 2013, 140, 195-205.	1.1	39
61	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. PLoS Genetics, 2014, 10, e1004285.	1.5	39
62	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
63	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
64	Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Nodeâ€“Negative Cohort. Clinical Cancer Research, 2008, 14, 4168-4174.	3.2	37
65	11q13 is a susceptibility locus for hormone receptor positive breast cancer. Human Mutation, 2012, 33, 1123-1132.	1.1	35
66	Investigation of geneâ€€environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. International Journal of Cancer, 2015, 136, E685-96.	2.3	34
67	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46 450 cases and 42 461 controls from the breast cancer association consortium. Human Molecular Genetics, 2014, 23, 1934-1946.	1.4	32
68	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	2.2	31
69	Elevated expression of podocalyxin is associated with lymphatic invasion, basal-like phenotype, and clinical outcome in axillary lymph node-negative breast cancer. Breast Cancer Research and Treatment, 2013, 137, 709-719.	1.1	30
70	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	5.8	30
71	Sclerosing Polycystic Sialadenopathy. JAMA Otolaryngology, 2004, 130, 357.	1.5	27
72	Confirmation of 5p12 As a Susceptibility Locus for Progesterone-Receptorâ€“Positive, Lower Grade Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2222-2231.	1.1	27

#	Article	IF	Citations
73	Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer, 2015, 15, 483.	1.1	27
74	Predictors of Outcome in Mammary Adenoid Cystic Carcinoma. American Journal of Surgical Pathology, 2020, 44, 214-223.	2.1	27
75	Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genomeâ€“wide interaction study. Endocrine-Related Cancer, 2013, 20, 875-887.	1.6	26
76	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	2.2	26
77	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
78	Current Morphologic Criteria Perform Poorly in Identifying Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome-associated Uterine Leiomyomas. International Journal of Gynecological Pathology, 2014, 33, 560-567.	0.9	25
79	Validation of Intratumoral T-bet+ Lymphoid Cells as Predictors of Disease-Free Survival in Breast Cancer. Cancer Immunology Research, 2016, 4, 41-48.	1.6	25
80	Use of Mismatch Repair Immunohistochemistry and Microsatellite Instability Testing. American Journal of Surgical Pathology, 2012, 36, 560-569.	2.1	23
81	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 308-316.	1.1	22
82	Endometrial Giant Cell Carcinoma: A Case Series and Review of the Spectrum of Endometrial Neoplasms Containing Giant Cells. American Journal of Surgical Pathology, 2010, 34, 1132-1138.	2.1	20
83	Breast specimen handling and reporting in the post-neoadjuvant setting: challenges and advances. Journal of Clinical Pathology, 2019, 72, 120-132.	1.0	20
84	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
85	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
86	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 1783-1791.	1.1	17
87	PGDS, A Novel Technique Combining Chromogenic In Situ Hybridization and Immunohistochemistry for the Assessment of ErbB2 (HER2/neu) Status in Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2007, 15, 316-324.	0.6	16
88	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
89	Invasive lobular carcinoma of the breast presenting as retroperitoneal fibrosis: a case report. Journal of Medical Case Reports, 2010, 4, 175.	0.4	15
90	MÃ¼llerian Adenosarcomas With Unusual Growth Patterns. International Journal of Gynecological Pathology, 2011, 30, 340-347.	0.9	15

#	Article	IF	Citations
91	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	2.2	14
92	CK8/18 expression, the basal phenotype, and family history in identifying BRCA1â€associated breast cancer in the Ontario site of the Breast Cancer Family Registry. Cancer, 2011, 117, 1350-1359.	2.0	13
93	Tumoral BRD4 expression in lymph node-negative breast cancer: association with T-bet+ tumor-infiltrating lymphocytes and disease-free survival. BMC Cancer, 2018, 18, 750.	1.1	13
94	Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer. Radiology, 2022, 304, 297-307.	3.6	13
95	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	1.4	12
96	Risk factors for uncommon histologic subtypes of breast cancer using centralized pathology review in the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2012, 134, 1209-1220.	1.1	10
97	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. Breast Cancer Research, 2011, 13, R14.	2.2	9
98	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. International Journal of Radiation Oncology Biology Physics, 2020, 108, 676-685.	0.4	9
99	PHIP- a novel candidate breast cancer susceptibility locus on 6q14.1. Oncotarget, 2017, 8, 102769-102782.	0.8	9
100	EMSY and CCND1 amplification in familial breast cancer: from the Ontario site of the Breast Cancer Family Registry. Breast Cancer Research and Treatment, 2011, 127, 831-839.	1.1	7
101	Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers. Applied Immunohistochemistry and Molecular Morphology, 2019, 27, 231-237.	0.6	7
102	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
103	Encapsulated Papillary Carcinoma of the Breast. Surgical Pathology Clinics, 2009, 2, 319-350.	0.7	5
104	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
105	Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumors. , 2011, , 121-138.		3
106	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	1.6	2
107	Fibroepithelial Lesions, Including Fibroadenoma and Phyllodes Tumor. , 2006, , 109-124.		2
108	Histological and immunohistochemical features to distinguish between adipocyte hyperplasia, atrophy and neoplasia: differential diagnosis of small round adipocytes in Crohnâ€™s disease. Histopathology, 2012, 61, 984-985.	1.6	1

#	Article	IF	Citations
109	Diseases of the Nipple. , 2006, , 139-148.		1
110	Core Biopsy. , 2011, , 19-27.		1
111	The characteristics associated with upgrade on surgical pathology of conventional imaging occult DCIS diagnosed by MRI. Breast Cancer Research and Treatment, 2021, 190, 317-327.	1.1	0